StockTipsArenaBeta

BUY Glenmark Pharmaceuticals — Rajesh Palviya, Axis Securities

BUYGlenmark Pharmaceuticals
Glenmark Pharmaceuticals share price target & all analyst calls

byRajesh Palviya, Axis SecuritiesHorizon: NA (inferred Swing (≤2wk))20 Aug 2026via ET Now

Entry₹2,334.6Inferred
Target₹2,390
Total upside +2.37% (call closed)
Stop loss₹2,310-1.05% risk
Exit₹2,31021 Aug 2026, 9:30 am
Stop-loss hit-1.05%
Follow Rajesh Palviya for new calls(27% target hit, 183 closed calls)Get alertsWatch GLENMARK for new buy/sell callsGet alertsSee 2 active Swing calls on GLENMARKSee 141 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 21 Aug 2026
4 supporting1 neutral1 opposing
Supports the BUY call (4)

Glenmark Pharmaceuticals Inc., USA has launched a new Calcium Gluconate Injection product in various strengths and vial sizes.

BSE · Company Update·21 Aug · today

(opens in new tab)

2 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·21 Aug · today

Glenmark Pharmaceuticals has received approval from the U.S. FDA for its Fluticasone Propionate Nasal Spray, 0.05 mg (50 mcg)/spray.

BSE · Company Update·20 Aug · yesterday

(opens in new tab)

3 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·20 Aug · yesterday

Neutral / worth noting (1)

Glenmark USA has agreed to a settlement of $15.28 million to resolve antitrust and consumer protection lawsuits related to price-fixing allegations. The company denies all allegations and states the s

BSE · Company Update·11 Aug · 1w ago

(opens in new tab)
Weighs against the BUY call (1)

Glenmark Pharma US arm agrees to $15.28 million settlement with Humana over antitrust lawsuits

NewsCnbc-Tv18·12 Aug · 1w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Glenmark Pharmaceuticals

All analyst calls on Glenmark Pharmaceuticals

More from Rajesh Palviya, Axis Securities

Every call and its outcome